Cantor Fitzgerald Reiterates Overweight on Catalyst Pharmaceuticals, Maintains $27 Price Target
Portfolio Pulse from richadhand@benzinga.com
Cantor Fitzgerald analyst Charles Duncan has reiterated an Overweight rating on Catalyst Pharmaceuticals (NASDAQ:CPRX) and maintained a price target of $27.
August 22, 2023 | 1:39 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated an Overweight rating on Catalyst Pharmaceuticals and maintained a price target of $27.
The reiteration of an Overweight rating by Cantor Fitzgerald indicates a positive outlook for Catalyst Pharmaceuticals. The maintained price target of $27 suggests that the analyst believes the stock has potential for growth. This could lead to increased investor confidence and potentially a rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100